Findings from a phase 2, placebo-controlled, double-blind, randomized withdrawal study - CONVEY -suggest that vixotrigine, a nonopioid investigational oral pain medication, can decrease chronic neuropathic pain due to small fiber neuropathy (SFN). The drug is generally well-tolerated.

The study included 265 patients with pain due to confirmed idiopathic or diabetes-associated SFN. After a 4-week open-label run-in period, 123 subjects - responders to vixotrigine- were randomized to receive 200 mg or 350 mg vixotrigine or placebo twice a day for a duration of 12 weeks. At week 12, the 200-mg dose met the primary endpoint of a statistically significant reduction in the mean average daily pain (ADP) score compared to placebo (P = .0501). In a subgroup analysis, a treatment effect was noted in participants with diabetes-associated SFN but not in those with idiopathic SFN. Additionally, there was a significant improvement in mean worst daily pain score at 12 weeks with the 200-mg dose, compared to placebo (P = .0455)… (Medscape)